01-04-2019 01:19 PM CET - Advertising, Media Consulting, Marketing Research
Print

Prostate Cancer Therapeutics Market Top Countries with Upcoming Business Opportunities 2025: Teva Pharmaceuticals, Sanofi, Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Astellas Pharma, Bayer, AstraZeneca, Dendreon, AbbVie, Ferring Pharmaceuticals

Press release from: Data Bridge Market Research
Prostate Cancer Therapeutics Market
Prostate Cancer Therapeutics Market
The report provides an all-inclusive analysis of the Prostate Cancer Therapeutics Market by types, applications, players, and regions. The Prostate Cancer Therapeutics report further illustrates the 2017-2025 production, consumption, revenue, gross margin, cost, gross, market share, CAGR, and market influencing factors of the Healthcare IT industry on the global level.

The aforementioned report is inclusive of all the company profiles of the top players and brands. Along with that, the report further covers a synopsis of market definition, classifications, and market trends. The Prostate Cancer Therapeutics Market drivers and restraints are derived with the help of SWOT analysis.

This report scope includes a holistic study of the current dynamics of the market, industry growth and restraints of the market. It provides the market forecast to 2025, recent developments in the market and pipeline analysis of the major players. The report also includes a review of micro and macro forecasts, new entrant strategies, and market penetration strategies with a comprehensive value chain analysis.

To request PDF sample copy of this report: databridgemarketresearch.com/request-a-sample/?dbmr=globa...

Report Overview:

On the basis of drug type
• Hormonal therapy,
• Luteinizing hormone-releasing hormone (lhrh) agonist,
• Anti-androgens,
• Immunotherapy,
• Targeted therapy,
• Chemotherapy

On the basis of distribution channel
• Hospital pharmacies,
• Retail pharmacies,
• Online pharmacies

Based on geography
• North america & south america,
• Europe,
• Asia-pacific
• Middle east & africa

The prostate cancer occurs in the prostate which is a small walnut shaped gland. The prostate cancer is most common type in men. Due to increase in awareness regarding the symptoms among the people, the market for the prostate cancer therapeutics is growing at a high growth rate. Various developments in advance science are helping in development of launch of various options for the treatment of this disease.

According to an article published recently by the cancer research institute in U.K., around 11,287 deaths were registered due to prostate cancer in U.K. The prostate cancer is the fourth most prevalent cancer globally. Various researches are made by the key player for the development of the therapies for the treatment of the cancer.

Click Here for Table of Content to Better Understanding of Report @ databridgemarketresearch.com/toc/?dbmr=global-prostate-ca...

The government is also taking various measures for the awareness regarding symptoms of the prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Hence, such initiatives by the government and the key players help in the growth of the market.

This reports includes the following deliverable

Macro Indicator Analysis
Market Overview
Market Dynamics
Drivers, Restraints, Opportunities and Challenges
Market sizing and growth analysis
Market forecasting to 2024
Market Competitive Landscape
Product Launches and Pipeline Analysis
Value Chain Analysis
Market Mergers, Acquisitions and Agreements
Company Profiles

Key Developments in the Market:

In May 2018, Ferring Pharmaceuticals has done an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy that is being developed by FKD Therapies Oy (FKD) as a treatment for patients with high-grade non-muscle invasive bladder cancer (NMIBC), who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. This option is exercisable on marketing approval from the US FDA. This will create a new US oncology division with the specialist knowledge and presence to introduce novel advanced therapies to the market.

Top Key Players:

• Tolmar INC,
• Ferring Pharmaceuticals,
• Takeda pharmaceutical co. Ltd.,
• Teva Pharmaceutical Industries LTD,
• Sanofi-Aventis, Pfizer Inc,
• Johnson & Johnson,
• IPSEN,
• Endo Pharmaceuticals Inc (Indevus Pharmaceuticals Inc) ,
• Dendreon Corporation,
• Abbott Laboratories,
• Bayer AG,
• Dendreon Corporation (Sanpower Group Co. Ltd.),
• AbbVie, Inc. among others.

Any Questions? Inquiry before Buying Visit @ databridgemarketresearch.com/inquire-before-buying/?dbmr=...

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.
News-ID: 1471820 • Views: 631
More releasesMore releases

You can edit or delete your press release here: